Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Hydrophilic Versus Lipophilic Statin Treatments in Patients With Renal Impairment After Acute Myocardial Infarction

View through CrossRef
Background Hydrophilic and lipophilic statins have similar efficacies in treating coronary artery disease. However, specific factors relevant to renal impairment and different arterial pathogeneses could modify the clinical effects of statin lipophilicity, and create differences in protective effects between statin types in patients with renal impairment. Methods and Results A total of 2062 patients with acute myocardial infarction with an estimated glomerular filtration rate <60 mL/min per 1.73 m 2 were enrolled from the Korea Acute Myocardial Infarction Registry between November 2011 and December 2015. The primary end point was a composite of 2‐year major adverse cardiac and cerebrovascular events (MACEs) after acute myocardial infarction occurrence. MACEs were defined as all‐cause death, recurrent myocardial infarction, revascularization, and stroke. Propensity‐score matching and Cox proportional hazards regression were performed. A total of 529 patients treated with hydrophilic statins were matched to 529 patients treated with lipophilic statins. There was no difference in the statin equivalent dose between the 2 statin groups. The cumulative event rate of MACEs, all‐cause mortality, and recurrent myocardial infarction were significantly lower in patients treated with hydrophilic statins in the propensity‐score matched population (all P <0.05). In the multivariable Cox regression analysis, patients treated with hydrophilic statins had a lower risk for composite MACEs (hazard ratio [HR], 0.70 [95% CI, 0.55–0.90]), all‐cause mortality (HR, 0.67 [95% CI, 0.49–0.93]), and recurrent myocardial infarction (HR, 0.40 [95% CI, 0.21–0.73]), but not for revascularization and ischemic stroke. Conclusions Hydrophilic statin treatment was associated with lower risk of MACEs and all‐cause mortality than lipophilic statin in a propensity‐score matched observational cohort of patients with renal impairment following acute myocardial infarction.
Title: Hydrophilic Versus Lipophilic Statin Treatments in Patients With Renal Impairment After Acute Myocardial Infarction
Description:
Background Hydrophilic and lipophilic statins have similar efficacies in treating coronary artery disease.
However, specific factors relevant to renal impairment and different arterial pathogeneses could modify the clinical effects of statin lipophilicity, and create differences in protective effects between statin types in patients with renal impairment.
Methods and Results A total of 2062 patients with acute myocardial infarction with an estimated glomerular filtration rate <60 mL/min per 1.
73 m 2 were enrolled from the Korea Acute Myocardial Infarction Registry between November 2011 and December 2015.
The primary end point was a composite of 2‐year major adverse cardiac and cerebrovascular events (MACEs) after acute myocardial infarction occurrence.
MACEs were defined as all‐cause death, recurrent myocardial infarction, revascularization, and stroke.
Propensity‐score matching and Cox proportional hazards regression were performed.
A total of 529 patients treated with hydrophilic statins were matched to 529 patients treated with lipophilic statins.
There was no difference in the statin equivalent dose between the 2 statin groups.
The cumulative event rate of MACEs, all‐cause mortality, and recurrent myocardial infarction were significantly lower in patients treated with hydrophilic statins in the propensity‐score matched population (all P <0.
05).
In the multivariable Cox regression analysis, patients treated with hydrophilic statins had a lower risk for composite MACEs (hazard ratio [HR], 0.
70 [95% CI, 0.
55–0.
90]), all‐cause mortality (HR, 0.
67 [95% CI, 0.
49–0.
93]), and recurrent myocardial infarction (HR, 0.
40 [95% CI, 0.
21–0.
73]), but not for revascularization and ischemic stroke.
Conclusions Hydrophilic statin treatment was associated with lower risk of MACEs and all‐cause mortality than lipophilic statin in a propensity‐score matched observational cohort of patients with renal impairment following acute myocardial infarction.

Related Results

Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract Background: A growing number of studies are claiming lipid-lowering medications (LLMs) primarily statins have anticancer properties to inhibit proliferation...
Predictors of statin adherence in primary care using real-world data
Predictors of statin adherence in primary care using real-world data
Abstract Purpose The objective of this study was to identify predictors of statin adherence in the primary and secondary preven...
Atheroma Progression in Hyporesponders to Statin Therapy
Atheroma Progression in Hyporesponders to Statin Therapy
Objective— Lowering low-density lipoprotein cholesterol (LDL-C) with statins has been demonstrated to slow plaque progression. This antiatherosclerotic effect in patien...
Clinical Characteristics of Renal Infarction in an Asian Population
Clinical Characteristics of Renal Infarction in an Asian Population
Introduction: Renal infarction is a rare and easily missed disease. There is even less meaningful information on renal infarction in the Asian population. Thus, the aim of this stu...

Back to Top